FindTrial
Sign In

Safety and efficacy in patients with uncontrolled asthma: systemitic review and meta-analysis

Safety and efficacy in patients with uncontrolled asthma: systemitic review and meta-analysis - Anti-IL-13 therapies in uncontrolled asthma

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000028977
Enrollment
1000
Registered
2017-09-04
Start date
2017-08-05
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

uncontrolled asthma

Interventions

None listed

Sponsors

Showa University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: RCTs that assessed the clinical efficacy and safety of anti-IL-13 therapies in adolescents or adults aged 12 years or older with a diagnosis of uncontrolled, severe, or moderate to severeasthma; and studies whose outcomes included pulmonary function, any adverse event, asthma exacerbation, asthma control, or asthma related quality of life.

Exclusion criteria

Exclusion criteria: Observational, case-control, cohort, and non-blinded clinical trials were excluded.

Design outcomes

Primary

MeasureTime frame
chenge in FEV1.0 incidence of all adverse events—

Secondary

MeasureTime frame
time to first asthma exacerbation change in ACQ score change in AQLQ—

Countries

Japan

Contacts

Public ContactShowa University

Showa University Division of Respiratory Medicine and Allergology, Department of Medicine

koichi-a@med.showa-u.ac.jp+81-3784-8532

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026